Close Menu

NEW YORK (GenomeWeb) – Great Basin Scientific today announced that it has signed a $20.5 million securities purchase agreement with institutional investors, which will provide the company with new funding for its ongoing operations.

Under the terms of the deal, the Salt Lake City-based molecular diagnostics firm will issue to the investors $22.1 million of senior convertible notes, as well as related common stock purchase warrants, equal to 16.6 percent of its issued and outstanding common stock, for gross aggregate proceeds of $18.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.

According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.

The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.

In Nature this week: the largest known collection of human genetic variants, and more.